drugset / Trial / NCT04007406
DP13 - A Phase II Study in Patients With Primary Aldosteronism
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.
Timeline
- Start
- 2019-11-21
- Primary completion
- 2022-05-02
- Completion
- 2022-05-02
Outcome
Met primary endpoint
registry analysis (superiority test); 4 mg DP13; p <0.0001; Mixed Models Analysis NCT04007406 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dexfadrostat phosphate | Unknown | 4 mg | — |
| Subject | dexfadrostat phosphate | Unknown | 8 mg | — |
| Subject | dexfadrostat phosphate | Unknown | 12 mg | — |